IRD

Opus Genetics, Inc. (IRD) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and a small molecule therapy (Phentolamine Ophthalmic Solution, or PS) for ophthalmic disorders. The company operates as a single segment focused on vision performance and health.

Key Financial Metrics

Note: Revenue is derived primarily from the Viatris License Agreement (reimbursement of R&D services and royalties). The Net Loss for YTD 2026 includes a significant non-cash fair value adjustment.

Material Changes vs. Prior Period

• Revenue Decline: License and collaboration revenue decreased by $4.3 million (60%) for the six months ended June 30, 2026, compared to the prior year. This was primarily due to a decrease in reimbursable research and development services for the PS program as clinical trials near completion.
• Increased Operating Expenses: Total operating expenses increased by $7.7 million year-over-year. Research and development (R&D) expenses rose by $7.8 million, driven by higher manufacturing and clinical costs for IRD programs (LCA5, BEST1), partially offset by lower PS-related costs.
• Significant Non-Cash Fair Value Expense: The YTD 2026 net loss was heavily impacted by a $44.2 million expense related to the fair value change of instruments (warrants and notes). In contrast, the prior year period recorded a $3.7 million gain in this category.
• Debt Financing: The company entered a new Note Purchase Agreement in April 2026, resulting in $35.0 million in long-term debt, compared to zero long-term debt in the prior year.

Guidance, Outlook, and Risks

• Liquidity: As of June 30, 2026, the company held $88.8 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
• Financing Activity: The company raised significant capital in the first half of 2026, including $35.0 million from a senior secured note, $25.0 million from a Series B preferred stock private placement (subsequently converted to common), and $5.0 million from a stock purchase agreement.
• Clinical Progress:
  • OPGx-LCA5: Enrollment for the registrational Phase 3 trial was completed in August 2026 (subsequent to period end), with dosing expected in Q4 2026.
  • OPGx-BEST1: Cohort 1 enrollment completed in May 2026; three-month topline data expected in September 2026.
  • PS (RYZUMVI): Viatris filed an sNDA for presbyopia in December 2025; FDA PDUFA date set for October 17, 2026.
• Risks: The company faces risks related to the volatility of warrant liabilities, which significantly impact reported net loss. Future profitability depends on regulatory approvals and commercialization of pipeline assets. The company has an accumulated deficit of $262.2 million.

Investor Verification Checklist

• Warrant Liability Volatility: Verify the sensitivity of the $62.1 million warrant liability to stock price and volatility changes, as this drives the majority of the reported net loss.
• Debt Covenants: Review the terms of the April 2026 Note Purchase Agreement, specifically the conversion features, interest payment structure (50% PIK initially), and milestone-based tranches.
• Revenue Sustainability: Assess the timeline for the decline in Viatris R&D reimbursement revenue and the potential for royalty revenue from RYZUMVI sales.
• Cash Burn Rate: Monitor the net cash used in operating activities ($24.7 million for YTD 2026) against the current cash balance to validate the 12-month liquidity runway.
• Upcoming Catalysts: Confirm the dates for the OPGx-BEST1 Cohort 1 data release (Sept 2026) and the RYZUMVI presbyopia PDUFA decision (Oct 2026).